Log in
Enquire now
Loxo Oncology

Loxo Oncology

A company that develops selective medicines for the treatment of cancer

OverviewStructured DataIssuesContributors

Contents

loxooncology.com
Is a
Organization
Organization
Company
Company

Company attributes

Industry
Engineering
Engineering
Biopharmaceutical
Biopharmaceutical
Cancer
Cancer
Diagnosis
Diagnosis
Pharmaceutical industry
Pharmaceutical industry
Enzyme kinetics
Enzyme kinetics
...
Location
Stamford, Connecticut
Stamford, Connecticut
0
New York City
New York City
0
B2X
B2B
B2B
0
CEO
Josh Bilenker
Josh Bilenker
AngelList URL
angel.co/loxo-oncology
Number of Employees (Ranges)
501 – 1,0000
Email Address
info@loxooncology.com0
Phone Number
+12036533880
Full Address
281 Tresser Blvd, 9th Floor, Stamford, CT 06901, US
CIK Number
1,581,7200
Place of Incorporation
Delaware
Delaware
0
IRS Number
462,996,6730
Founded Date
2013
0
Total Funding Amount (USD)
33,000,000
Latest Funding Round Date
October 3, 2013
Latest Funding Type
Series A
Series A
Patents Assigned (Count)
14
Wellfound ID
loxo-oncology
Country
United States
United States
0

Other attributes

Company Operating Status
Active
Public/Private
Public0
SIC Code
2,8340
No article content yet.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more companies like Loxo Oncology

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.